| Assessment Status | Rapid Review Complete |
| HTA ID | 21015 |
| Drug | Formoterol fumarate dihydrate, glycopyrronium, budesonide |
| Brand | Trixeo Aerosphere® |
| Indication | For the maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. |
| Assessment Process | |
| Rapid review commissioned | 06/05/2021 |
| Rapid review completed | 30/04/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that for/gly/bud (Trixeo Aerosphere ®) be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement September 2021.
